Tumor-specific neoantigen peptide–MHC class II complex (NeoAg-MHC II complex)

Tumor-specific neoantigen peptide–MHC class II complexes are molecular structures formed when mutated proteins unique to cancer cells are processed and presented on the cell surface by Major Histocompatibility Complex (MHC) class II molecules (Nature, 2015). Unlike MHC class I, which primarily presents to CD8+ cytotoxic T cells, MHC class II complexes interact with CD4+ helper T cells, which are critical for orchestrating a comprehensive anti-tumor immune response, including the activation of B cells and the enhancement of CD8+ T cell function (Frontiers in Immunology, 2024). These complexes are highly tumor-specific because the peptides are derived from somatic mutations not present in the germline, making them ideal targets for precision immunotherapies such as personalized vaccines (e.g., mRNA-4157) and TCR-engineered T cell therapies (NIH, 2018). Therapeutic strategies targeting these complexes aim to stimulate a robust, mutation-specific immune response while avoiding the off-target effects associated with traditional treatments (Nature Communications, 2025). However, challenges remain, including the accurate prediction of MHC II binding and the potential for tumor escape through the downregulation of MHC expression or the induction of regulatory T cells (Frontiers in Immunology, 2024).

Other names

Neoepitope-MHC II complexMutant peptide-MHC II complexTSA-MHC II complexTumor-specific antigen-HLA class II complexNeoantigen-HLA class II complex

Activation of CD4+ T cells through T cell receptor (TCR) recognition of the peptide-MHC complex, leading to cytokine secretion and orchestration of anti-tumor immunity.